A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | MicrobiomeTrials

← Back to trials

NCT07205822

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-10-30Est. Completion: 2028-02-02

Enrollment target: 100 participants

Locations

Research Site, Largo, Florida, United States
Research Site, Fort Wayne, Indiana, United States
Research Site, Omaha, Nebraska, United States
Research Site, New York, New York, United States
Research Site, Houston, Texas, United States
Research Site, Puyallup, Washington, United States
Research Site, Beijing, China
Research Site, Changsha, China
Research Site, Guangzhou, China
Research Site, Linyi, China
Research Site, Shandong, China
Research Site, Wuhan, China
Research Site, Zhengzhou, China
Research Site, Clermont-Ferrand, France
Research Site, La Roche-sur-Yon, France
Research Site, Montpellier, France
Research Site, Paris, France
Research Site, Pierre-Bénite, France
Research Site, Aviano, Italy
Research Site, Florence, Italy
Research Site, Meldola, Italy

Other microbiome trials you might be interested in

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain MetastasesRecruiting

Breast CancerBreast CarcinomaCancer of the BreastMalignant Neoplasm of Breast

Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or bra…

Bethesda, United StatesEst. completion Jul 1, 2033

Comparison of CE-DBT and MRI in Patients With Known Breast LesionsEARLY_PHASE1TERMINATED

Breast Cancer

The purpose of this pilot study is to compare radiologist confidence level in evaluating patients with known breast lesi…

Chapel Hill, United StatesCompleted May 20, 2026

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.